CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer

Cell Reports

Volumn 15, Issue 12, 2016, Pages 2719-2732

  Byrne, Katelyn T ^a   Vonderheide, Robert H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; INFLAMMASOME; INTERFERON; TOLL LIKE RECEPTOR; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTIBODY; DEOXYCYTIDINE; GAMMA INTERFERON; GEMCITABINE; PACLITAXEL;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL STIMULATION; CELLULAR IMMUNITY; CELLULAR IMMUNODEFICIENCY; CONTROLLED STUDY; FEMALE; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANIMAL; ANTIGEN PRESENTING CELL; C57BL MOUSE; CARCINOMA, PANCREATIC DUCTAL; CELL CLONE; DRUG EFFECTS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE SUBPOPULATION; METABOLISM; NEOPLASM; PANCREATIC NEOPLASMS; PATHOLOGY; T LYMPHOCYTE; TREATMENT OUTCOME;

ALBUMINS; ANIMALS; ANTIBODIES; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; CARCINOMA, PANCREATIC DUCTAL; CD8-POSITIVE T-LYMPHOCYTES; CLONE CELLS; DEOXYCYTIDINE; IMMUNITY, INNATE; INTERFERON-GAMMA; LYMPHOCYTE SUBSETS; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; PACLITAXEL; PANCREATIC NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84975105592     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.05.058     Document Type: Article

References (70)

1. Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., Vasilakos J.P., Noelle R.J., Kedl R.M. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med. 2004, 199:775-784.
2. Ahonen C.L., Wasiuk A., Fuse S., Turk M.J., Ernstoff M.S., Suriawinata A.A., Gorham J.D., Kedl R.M., Usherwood E.J., Noelle R.J. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 2008, 111:3116-3125.
3. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Børresen-Dale A.L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421. Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer ConsortiumICGC Breast Cancer Consortium, ICGC MMML-Seq ConsortiumICGC MMML-Seq Consortium, ICGC PedBrainICGC PedBrain.
4. Alvarez R., Musteanu M., Garcia-Garcia E., Lopez-Casas P.P., Megias D., Guerra C., Muñoz M., Quijano Y., Cubillo A., Rodriguez-Pascual J., et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer 2013, 109:926-933.
5. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
6. Bajor D.L., Xu X., Torigian D.A., Mick R., Garcia L.R., Richman L.P., Desmarais C., Nathanson K.L., Schuchter L.M., Kalos M., Vonderheide R.H. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol. Res. 2014, 2:1051-1058.
7. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., Huhn R.D., Song W., Li D., Sharp L.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
8. Beatty G.L., Torigian D.A., Chiorean E.G., Saboury B., Brothers A., Alavi A., Troxel A.B., Sun W., Teitelbaum U.R., Vonderheide R.H., O'Dwyer P.J. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2013, 19:6286-6295.
9. Beatty G.L., Winograd R., Evans R.A., Long K.B., Luque S.L., Lee J.W., Clendenin C., Gladney W.L., Knoblock D.M., Guirnalda P.D., Vonderheide R.H. Exclusion of T Cells from pancreatic carcinomas in mice Is regulated by Ly6C(low) F4/80(+) extratumoral macrophages. Gastroenterology 2015, 149:201-210.
10. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478-480.
11. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
12. Ciampricotti M., Hau C.S., Doornebal C.W., Jonkers J., de Visser K.E. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat. Med. 2012, 18:344-346. author reply 346.
13. Clark C.E., Hingorani S.R., Mick R., Combs C., Tuveson D.A., Vonderheide R.H. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007, 67:9518-9527.
14. Cobbold M., De La Peña H., Norris A., Polefrone J.M., Qian J., English A.M., Cummings K.L., Penny S., Turner J.E., Cottine J., et al. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci. Transl. Med. 2013, 5:203ra125.
15. Commisso C., Davidson S.M., Soydaner-Azeloglu R.G., Parker S.J., Kamphorst J.J., Hackett S., Grabocka E., Nofal M., Drebin J.A., Thompson C.B., et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013, 497:633-637.
16. Corrales L., Gajewski T.F. Molecular pathways: targeting the stimulator of interferon genes (STING) in the immunotherapy of cancer. Clin. Cancer Res. 2015, 21:4774-4779.
17. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
18. Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., Li X.D., Mauceri H., Beckett M., Darga T., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced Type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41:843-852.
19. Diehl L., den Boer A.T., Schoenberger S.P., van der Voort E.I., Schumacher T.N., Melief C.J., Offringa R., Toes R.E. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 1999, 5:774-779.
20. Dieu-Nosjean M.C., Goc J., Giraldo N.A., Sautès-Fridman C., Fridman W.H. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014, 35:571-580.
21. Ding A., Sanchez E., Nathan C.F. Taxol shares the ability of bacterial lipopolysaccharide to induce tyrosine phosphorylation of microtubule-associated protein kinase. J. Immunol. 1993, 151:5596-5602.
22. Emens L.A., Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol. Res. 2015, 3:436-443.
23. Feig C., Jones J.O., Kraman M., Wells R.J., Deonarine A., Chan D.S., Connell C.M., Roberts E.W., Zhao Q., Caballero O.L., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2013, 110:20212-20217.
24. French R.R., Chan H.T., Tutt A.L., Glennie M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 1999, 5:548-553.
25. Frese K.K., Neesse A., Cook N., Bapiro T.E., Lolkema M.P., Jodrell D.I., Tuveson D.A. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012, 2:260-269.
26. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
27. Green D.R., Ferguson T., Zitvogel L., Kroemer G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 2009, 9:353-363.
28. Gubin M.M., Schreiber R.D. CANCER. The odds of immunotherapy success. Science 2015, 350:158-159.
29. Herbst R.S., Soria J.C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
30. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483.
31. Ishwaran H., Kogalur U.B. Consistency of random survival forests. Stat. Probab. Lett. 2010, 80:1056-1064.
32. Jin L., Getahun A., Knowles H.M., Mogan J., Akerlund L.J., Packard T.A., Perraud A.L., Cambier J.C. STING/MPYS mediates host defense against Listeria monocytogenes infection by regulating Ly6C(hi) monocyte migration. J. Immunol. 2013, 190:2835-2843.
33. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
34. Kaczanowska S., Joseph A.M., Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J. Leukoc. Biol. 2013, 93:847-863.
35. Keenan B.P., Saenger Y., Kafrouni M.I., Leubner A., Lauer P., Maitra A., Rucki A.A., Gunderson A.J., Coussens L.M., Brockstedt D.G., et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 2014, 146:1784-1794.e6.
36. Le D.T., Wang-Gillam A., Picozzi V., Greten T.F., Crocenzi T., Springett G., Morse M., Zeh H., Cohen D., Fine R.L., et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 2015, 33:1325-1333.
37. Lo A., Wang L.C., Scholler J., Monslow J., Avery D., Newick K., O'Brien S., Evans R.A., Bajor D.J., Clendenin C., et al. Tumor-promoting desmoplasia Is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 2015, 75:2800-2810.
38. Long K.B., Gladney W.L., Tooker G.M., Graham K., Fraietta J.A., Beatty G.L. IFN-gamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov. 2016, 6:400-413.
39. Lutz E.R., Wu A.A., Bigelow E., Sharma R., Mo G., Soares K., Solt S., Dorman A., Wamwea A., Yager A., et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol. Res. 2014, 2:616-631.
40. Massó-Vallés D., Jauset T., Serrano E., Sodir N.M., Pedersen K., Affara N.I., Whitfield J.R., Beaulieu M.E., Evan G.I., Elias L., et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res. 2015, 75:1675-1681.
41. Melero I., Grimaldi A.M., Perez-Gracia J.L., Ascierto P.A. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin. Cancer Res. 2013, 19:997-1008.
42. Nazarov V.I., Pogorelyy M.V., Komech E.A., Zvyagin I.V., Bolotin D.A., Shugay M., Chudakov D.M., Lebedev Y.B., Mamedov I.Z. tcR: an R package for T cell receptor repertoire advanced data analysis. BMC Bioinformatics 2015, 16:175.
43. Neesse A., Frese K.K., Chan D.S., Bapiro T.E., Howat W.J., Richards F.M., Ellenrieder V., Jodrell D.I., Tuveson D.A. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 2014, 63:974-983.
44. Nowak A.K., Robinson B.W., Lake R.A. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003, 63:4490-4496.
45. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393:474-478.
46. Rook A.H., Gelfand J.M., Wysocka M., Troxel A.B., Benoit B., Surber C., Elenitsas R., Buchanan M.A., Leahy D.S., Watanabe R., et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood 2015, 126:1452-1461.
47. Ryan S.O., Turner M.S., Gariépy J., Finn O.J. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res. 2010, 70:5788-5796.
48. Sauer J.D., Sotelo-Troha K., von Moltke J., Monroe K.M., Rae C.S., Brubaker S.W., Hyodo M., Hayakawa Y., Woodward J.J., Portnoy D.A., Vance R.E. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 2011, 79:688-694.
49. Sausen M., Phallen J., Adleff V., Jones S., Leary R.J., Barrett M.T., Anagnostou V., Parpart-Li S., Murphy D., Kay Li Q., et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat. Commun. 2015, 6:7686.
50. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
51. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015, 348:56-61.
52. Shi J., Zhao Y., Wang Y., Gao W., Ding J., Li P., Hu L., Shao F. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 2014, 514:187-192.
53. Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., Vitale I., Goubar A., Baracco E.E., Remédios C., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 2014, 20:1301-1309.
54. Soares K.C., Rucki A.A., Wu A.A., Olino K., Xiao Q., Chai Y., Wamwea A., Bigelow E., Lutz E., Liu L., et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J. Immunother. 2015, 38:1-11.
55. Sotomayor E.M., Borrello I., Tubb E., Rattis F.M., Bien H., Lu Z., Fein S., Schoenberger S., Levitsky H.I. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 1999, 5:780-787.
56. Stromnes I.M., Schmitt T.M., Hulbert A., Brockenbrough J.S., Nguyen H.N., Cuevas C., Dotson A.M., Tan X., Hotes J.L., Greenberg P.D., Hingorani S.R. T Cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 2015, 28:638-652.
57. Summers deLuca L., Gommerman J.L. Fine-tuning of dendritic cell biology by the TNF superfamily. Nat. Rev. Immunol. 2012, 12:339-351.
58. Tran E., Ahmadzadeh M., Lu Y.C., Gros A., Turcotte S., Robbins P.F., Gartner J.J., Zheng Z., Li Y.F., Ray S., et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015, 350:1387-1390.
59. Twyman-Saint Victor C., Rech A.J., Maity A., Rengan R., Pauken K.E., Stelekati E., Benci J.L., Xu B., Dada H., Odorizzi P.M., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520:373-377.
60. van Mierlo G.J., den Boer A.T., Medema J.P., van der Voort E.I., Fransen M.F., Offringa R., Melief C.J., Toes R.E. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. USA 2002, 99:5561-5566.
61. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., Korn R.L., Desai N., Trieu V., Iglesias J.L., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 2011, 29:4548-4554.
62. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., Seay T., Tjulandin S.A., Ma W.W., Saleh M.N., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013, 369:1691-1703.
63. Vonderheide R.H., Glennie M.J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 2013, 19:1035-1043.
64. Vonderheide R.H., Flaherty K.T., Khalil M., Stumacher M.S., Bajor D.L., Hutnick N.A., Sullivan P., Mahany J.J., Gallagher M., Kramer A., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 2007, 25:876-883.
65. Westcott P.M., Halliwill K.D., To M.D., Rashid M., Rust A.G., Keane T.M., Delrosario R., Jen K.Y., Gurley K.E., Kemp C.J., et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 2015, 517:489-492.
66. Winograd R., Byrne K.T., Evans R.A., Odorizzi P.M., Meyer A.R., Bajor D.L., Clendenin C., Stanger B.Z., Furth E.E., Wherry E.J., Vonderheide R.H. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol. Res. 2015, 3:399-411.
67. Woo S.R., Fuertes M.B., Corrales L., Spranger S., Furdyna M.J., Leung M.Y., Duggan R., Wang Y., Barber G.N., Fitzgerald K.A., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41:830-842.
68. Woodward J.J., Iavarone A.T., Portnoy D.A. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 2010, 328:1703-1705.
69. Zhu Y., Knolhoff B.L., Meyer M.A., Nywening T.M., West B.L., Luo J., Wang-Gillam A., Goedegebuure S.P., Linehan D.C., DeNardo D.G. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014, 74:5057-5069.
70. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008, 8:59-73.